enobosarm
Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition in people taking GLP-1 receptor agonists like semaglutide. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress urinary incontinence, but development for all other uses has been discontinued. Enobosarm was evaluated for the treatment of muscle wasting related to cancer in late-stage clinical trials, and the drug improved lean body mass in these trials, but it was not effective in improving muscle strength. As a result, enobosarm was not approved and development for this use was terminated. Enobosarm is taken by mouth. — Wikipedia
Clinical trial activity
16 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2007 (NCT00467844)
Timeline
Indications
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
SARM
Chemistry & pharmacology
SMILES
C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1- Mol. weight
- 389.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnobosarm ↗
- ChEMBLCHEMBL1738889 ↗
Also known as
- enobosarm
- enobosarm
- enobosarm
- enobosarm
- enobosarm
- gtx 024
- gtx-024
- gtx-024
- gtx-024
- gtx-024
- mk2866
- mk 2866
- mk-2866
- mk-2866
- mk-2866
- ostarine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06282458 | Phase 2 | Apr 29, 2024 | Veru Inc. |
| NCT05065411 | Phase 2 | Nov 30, 2021 | Veru Inc. |
| NCT04869943 | Phase 3 | Oct 12, 2021 | Veru Inc. |
| NCT03566290 | Phase 2 | Jun 28, 2018 | GTx, Oakland University |
| NCT03508648 | Phase 2 | May 28, 2018 | GTx, Oakland University |
| NCT03241342 | Phase 2 | Aug 21, 2017 | GTx, Oakland University |
| NCT02971761 | Phase 2 | Apr 3, 2017 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03264651 | Phase 1 | Feb 1, 2017 | GTx, Havah Therapeutics Pty Ltd |
| NCT02746328 | Phase 2 | Apr 1, 2016 | GTx, University of Washington |
| NCT02658448 | Phase 2 | Jan 1, 2016 | GTx, United States Army |
| NCT02463032 | Phase 2 | Aug 1, 2015 | GTx, Harvard University |
| NCT02368691 | Phase 2 | Jun 1, 2015 | GTx, University of California, San Francisco |
| NCT01616758 | Phase 2 | Apr 1, 2013 | GTx |
| NCT01355497 | Phase 3 | Jul 1, 2011 | GTx |
| NCT01355484 | Phase 3 | Jul 1, 2011 | GTx |
| NCT00467844 | Phase 2 | May 1, 2007 | GTx |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GTx | For profit | 12 | 11 | 3 | 2007 |
| Oakland University | Academic/Hospital | 3 | 0 | 1 | 2017 |
| Veru Inc. | For profit | 3 | 3 | 2 | 2021 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Havah Therapeutics Pty Ltd | For profit | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| United States Army | Government | 1 | 0 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2016 |